3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
102
Neoplasm Metastasis
13
Neoplasms
6
Triple Negative Breast Neoplasms
5
Breast Diseases
5
Neoplasms by Site
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Unilateral Breast Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms, Male
2
Breast Cancer Female
2
Advanced Breast Cancer
2
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Interventions
Trastuzumab
5
Carboplatin
5
Docetaxel
4
pertuzumab
3
Paclitaxel
3
Cyclophosphamide
3
pembrolizumab
2
Epirubicin
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
taxane
1
talazoparib
1
sarilumab
1
pyrotinib
1
pirarubicin
1
pexidartinib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
abemaciclib
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled